Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,146 public trials 2,034 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Recruiting

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

NCT06993675

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Yale University New Haven, Connecticut, United States

Wilmot Cancer Center, Clinical Trial Office of the University of Rochester Medical Center Rochester, New York, United States

View Trial Details

Recruiting

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

NCT07454226

Conditions: Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations: Blood diseases hospital Tianjin, Tianjin Municipality, China

View Trial Details

Recruiting

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

NCT07052305

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations: Washington University School of Medicine St Louis, Missouri, United States

View Trial Details

Recruiting

Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies

NCT07584889

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B Cell Lymphoma, +16 more
Locations: Shenzhen University General Hospital Shenzhen, Other (Non U.s.), China

View Trial Details

Recruiting

Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

NCT07299149

Conditions: Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations: Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin 300020 Tianjin, Tianjin Municipality, China

Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China

View Trial Details

Recruiting

MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity

NCT07582354

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: IRCCS AOU Policlinico Sant'Orsola Bologna, Bo, Italy

View Trial Details

Recruiting

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

NCT07582432

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +24 more
Locations: Study Site 102 St. Petersburg, Florida, United States

Study Site 101 Fort Wayne, Indiana, United States

Study Site 105 Westbrook, Maine, United States

Study Site 104 Columbus, Ohio, United States

View Trial Details

Recruiting

CD70-targeted immunoPET Imaging of Malignant Cancers

NCT06852638

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +37 more
Locations: Renji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, China

View Trial Details

Recruiting

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

NCT07579234

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations: Institute of Hematology & Blood Diseases Hospital Tianjing, China

View Trial Details

Recruiting

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06896916

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Beverly Hills Cancer Center /ID# 266921 Beverly Hills, California, United States

Colorado Blood Cancer Institute /ID# 273751 Denver, Colorado, United States

Washington University /ID# 266972 St Louis, Missouri, United States

Rutgers Cancer Institute of New Jersey /ID# 266833 New Brunswick, New Jersey, United States

View all 27 locations

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions